Pianzumab plus AVD for newly diagnosed advanced Hodgkin lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether adding pianzumab to standard AVD chemotherapy works better for newly diagnosed advanced classic Hodgkin lymphoma. It may help people control the cancer and prevent it from coming back, and it will compare outcomes while tracking side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (18+) and have good performance status (ECOG 0–1).
- Your diagnosis is classic Hodgkin lymphoma confirmed by biopsy (not the other types).
- Your lymphoma is advanced (Ann Arbor stage III–IV, or stage IIB) with at least one high-risk feature, such as a very large mediastinal/thorax mass or a mass bigger than 10 cm.
- You have not had any prior whole-body (systemic) treatment for classic Hodgkin lymphoma.
- You have measurable disease, and your main organs are strong enough for chemotherapy.
- You agree to use effective birth control during the study and for 6 months after; pregnancy test is negative before starting, and participants must not be breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, AK129, alone or with another drug called AK117, for people with classic Hodgkin lymphoma that has not responded to or stopped responding to PD-1/L1 inhibitor therapy. The goal is to see if these combinations can help control the cancer.
This trial tests a combination of the immunotherapy drug pembrolizumab with chemotherapy for people with newly diagnosed Hodgkin lymphoma who are too frail for standard treatment. The goal is to find a safer, effective option for patients who are older or have other health issues.
This trial studies whether adding zimberelimab (an immune system drug) to standard AVD chemotherapy works better for newly diagnosed early-stage Hodgkin lymphoma. It may help improve control of the cancer, especially when it can’t be fully cured with simpler treatment alone.
This trial tests a combination of the immunotherapy drug sintilimab with chemotherapy (AVD) for children and teens with newly diagnosed low- or intermediate-risk Hodgkin lymphoma. The goal is to see if adding sintilimab can improve outcomes while reducing side effects.
This trial tests a newer, lower-dose immunotherapy combination (AVD plus nivolumab) against a standard intensive chemo regimen (BEACOPP) that is adjusted based on PET scan results. It is for people with advanced classical Hodgkin lymphoma that has not been treated before.
This trial tests a combination of nivolumab and chemotherapy (AVD) for people newly diagnosed with advanced classic Hodgkin lymphoma. The goal is to see if adding nivolumab improves treatment outcomes.
Hear when a new Classic Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.